We are live on ! Find out more
AIMT

Aimmune Therapeutics
AIMT

Delisted

AIMT was delisted on the 12th of October, 2020.

Back to rankings

96 hedge funds and large institutions have $757M invested in Aimmune Therapeutics in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 45 increasing their positions, 21 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 21

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

7% more funds holding

Funds holding: 90 → 96 (+6)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

2% less capital invested

Capital invested by funds: $771M → $757M (-$13.5M)

Holders
96
Holders Change
+6
Holders Change %
+6.67%
% of All Funds
2.39%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
13
Increased
45
Reduced
21
Closed
7
Calls
$252K
Puts
–
Net Calls
+$252K
Net Calls Change
-$51K

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$13.7M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$12.6M
3
BlackRock
BlackRock
New York
+$9M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$6M
5
GPP
Great Point Partners
Connecticut
+$5.97M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$50.3M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.14M
3
Credit Agricole
Credit Agricole
France
-$8.99M
4
TG
TLP Group
Illinois
-$1.91M
5
AG
Artal Group
Luxembourg
-$1.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
CWG
26
C WorldWide Group
Denmark
$5.12M +$1.16M +60,700 +32%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$4.93M +$620K +32,484 +16%
Goldman Sachs
28
Goldman Sachs
New York
$4.67M +$2.53M +132,603 +140%
Bank of America
29
Bank of America
North Carolina
$4.29M +$317K +16,607 +9%
ERSOT
30
Employees Retirement System of Texas
Texas
$4M – – –
Hudson Bay Capital Management
31
Hudson Bay Capital Management
Connecticut
$3.29M +$3.05M +160,000 New
Bank of New York Mellon
32
Bank of New York Mellon
New York
$2.7M +$363K +19,016 +17%
Deutsche Bank
33
Deutsche Bank
Germany
$2.34M +$696K +36,472 +47%
Charles Schwab
34
Charles Schwab
California
$2.17M +$355K +18,632 +21%
AG
35
Artal Group
Luxembourg
$2.06M -$1.56M -81,600 -45%
SCA
36
Secor Capital Advisors
New York
$1.99M +$1.84M +96,619 New
American Century Companies
37
American Century Companies
Missouri
$1.99M -$222K -11,638 -11%
TCIM
38
TIAA CREF Investment Management
New York
$1.96M +$462K +24,226 +34%
CCI
39
Columbus Circle Investors
$1.91M +$984K +51,604 +125%
TA
40
Teachers Advisors
New York
$1.3M +$357K +18,688 +42%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$1.28M +$200K +10,500 +20%
Wells Fargo
42
Wells Fargo
California
$1.22M -$19.1K -999 -2%
Invesco
43
Invesco
Georgia
$1.16M +$1.07M +56,197 New
Victory Capital Management
44
Victory Capital Management
Texas
$993K -$13K -680 -1%
AA
45
ALPS Advisors
Colorado
$933K +$43.9K +2,302 +5%
Connor, Clark & Lunn Investment Management (CC&L)
46
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$911K +$659K +34,525 +352%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$813K +$189K +9,928 +34%
PMLI
48
Penn Mutual Life Insurance
Pennsylvania
$801K – – –
TD Asset Management
49
TD Asset Management
Ontario, Canada
$783K +$122K +6,400 +20%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$773K +$204K +10,699 +40%
1
2
3 4 5

AIMT Hedge Fund Activity: Q2 2017 in Review

96 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q2 2017, worth a combined $757M — down 1.8% from $771M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AIMT positions and 7 closed out — a net gain of 6 holders — while 45 added to existing stakes and 21 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $13.7M. The largest seller was Wellington Management Group, exiting entirely with an estimated $50.3M sold.

  • 96 institutional investors held Aimmune Therapeutics (AIMT) as of Q2 2017, up from 90 in Q1 2017.
  • Funds reported $757M of Aimmune Therapeutics stock for Q2 2017, down 1.8% quarter-over-quarter.
  • 13 funds opened new Aimmune Therapeutics positions in Q2 2017 and 7 closed out, a net change of +6 holders.
  • The largest Aimmune Therapeutics buyer in Q2 2017 was Eventide Asset Management, an estimated $13.7M added.
  • The largest Aimmune Therapeutics seller in Q2 2017 was Wellington Management Group, an estimated $50.3M sold.

Based on aggregated 13F filings for Q2 2017.